On May 30, 2025, Fortress Biotech, Inc. completed the merger of its subsidiary Checkpoint Therapeutics with Sun Pharmaceutical Industries, receiving approximately $28 million in proceeds and potential additional payments up to $4.8 million based on regulatory milestones. This transaction marks Checkpoint's deconsolidation as a subsidiary of Fortress.